From a pharmacology standpoint, Fosfestrol is identified as a phosphorylated estrogenic compound. A prodrug related to estrogenic compounds; suppresses androgen signaling through endocrine feedback and direct hormonal effects. That mechanism helps explain its clinical placement in Historically used in advanced prostate cancer in some regions; current availability/approval is jurisdiction-dependent. The therapeutic effect is tied to estrogen or other hormone signaling, so receptor status, menopausal context, and disease setting help define its place in treatment. The database records the medicine as Hormonal / Endocrine Therapy and links it with Prostate Cancer. Its listed combinations include Historically used hormonal therapy; not a standard contemporary first-line regimen in most major guidelines. In practice, the surrounding regimen matters because the same agent can be used with different partners or at different points in a treatment pathway depending on the malignancy. The database places it within endocrine management, where the hormonal environment and disease state are important determinants of clinical use. Any selection criterion written into the indication?such as receptor status, mutation, disease stage, treatment history, or response to prior therapy?should be treated as part of the use definition. The medicine should also be distinguished from agents with similar class names but different molecular targets or clinical roles. Current regulatory information and disease-specific guidelines remain the appropriate sources for confirming present-day use.